Oncolytic adenovirus

Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting

Retrieved on:

Monday, April 22, 2024

Combination, Cancer, FOLFIRINOX, Pancreatic cancer, Poster, Animal, Irinotecan, Cell, PDAC, Real-time, Therapy, Patient, Gene, Society, Neoplasm, Oncolytic adenovirus, Pharmaceutical industry

ROCKVILLE, Md., April 22, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the presentation of preclinical data demonstrating enhanced anti-tumor effects in human pancreatic cancer xenograft-bearing mice treated with lead product candidate VCN-01 and liposomal irinotecan. These data support the potential synergy of VCN-01 and first-line pancreatic cancer chemotherapy regimens, and will be featured in a poster presentation at the American Society for Cell and Gene Therapy (ASGCT) 27th Annual Meeting, being held both virtually and in Baltimore from May 7-11, 2024.

Key Points:

These data support the potential synergy of VCN-01 and first-line pancreatic cancer chemotherapy regimens, and will be featured in a poster presentation at the American Society for Cell and Gene Therapy (ASGCT) 27th Annual Meeting, being held both virtually and in Baltimore from May 7-11, 2024.
“We look forward to leveraging these findings and evaluating the combination of VCN-01 with additional first-line pancreatic cancer chemotherapy regimens, including NALIRIFOX and FOLFIRINOX.
In vivo: Synergy of VCN-01 plus liposomal irinotecan was observed in animals bearing subcutaneous human pancreatic tumors.
Combination therapy with VCN-01 + liposomal irinotecan at either dose displayed significantly reduced tumor growth compared to each treatment alone.

Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting

Retrieved on:

Monday, April 8, 2024

Combination, Irinotecan, Patient, Gene, FOLFIRINOX, Oncolytic adenovirus, Cancer, PDAC, Society, Therapy, Cell, Pharmaceutical industry

Data will be featured in a poster presentation at the American Society for Cell and Gene Therapy (ASGCT) 27th Annual Meeting, being held both virtually and in Baltimore from May 7-11, 2024.

Key Points:

Data will be featured in a poster presentation at the American Society for Cell and Gene Therapy (ASGCT) 27th Annual Meeting, being held both virtually and in Baltimore from May 7-11, 2024.
“We look forward to presenting data at the upcoming ASGCT meeting that further highlight the potential of our systemically administered oncolytic adenovirus, VCN-01, to synergistically combine with an expanding range of standard-of-care chemotherapies for difficult-to-treat cancers,” said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics.
“ Our on-going VIRAGE Phase 2b trial is evaluating VCN-01 in combination with gemcitabine/nab-paclitaxel to treat metastatic pancreatic ductal adenocarcinoma (PDAC).
ET

Tetherex Pharmaceuticals Signs Exclusive Worldwide License with Mayo Clinic for Development and Commercialization of a Novel Single-Cycle Adenovirus Vaccine Platform

Retrieved on:

Tuesday, July 6, 2021

Medicine, Medical specialties, Health, Adenoviridae, Virology, Vaccine, Virus, GRAd-COV2, Oncolytic adenovirus

OKLAHOMA CITY, July 6,2021 /PRNewswire/ --Tetherex Pharmaceuticals, Inc., a privately held, clinical stage biopharmaceutical company developing novel selectin inhibitor products to treat inflammatory diseases, today announced that it has executed an exclusive worldwide license with Mayo Clinic for the development and commercialization of a novel single-cycle adenovirus vaccine platform.

Key Points:

OKLAHOMA CITY, July 6,2021 /PRNewswire/ --Tetherex Pharmaceuticals, Inc., a privately held, clinical stage biopharmaceutical company developing novel selectin inhibitor products to treat inflammatory diseases, today announced that it has executed an exclusive worldwide license with Mayo Clinic for the development and commercialization of a novel single-cycle adenovirus vaccine platform.
The platform will be used to target multiple infectious diseases, beginning with a Phase 1 clinical study investigating a vaccine for COVID-19.
The single-cycle adenovirus platform was developed to enhance the expression of target antigens, amplifying immune responses to infectious disease targets.
Preclinical studies have demonstrated that the single-cycle adenovirus can markedly increase target antigen expression over that of currently utilized replication defective adenovirus vaccines.

TILT Biotherapeutics Submits IND for Phase I Trial of Immunotherapeutic TILT-123 in Ovarian Cancer

Retrieved on:

Monday, June 14, 2021

Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Cancer treatments, Clinical medicine, Medicine, Virotherapy, Biotechnology, Experimental cancer treatments, Cancer immunotherapy, Adenoviridae, Pembrolizumab, Oncolytic adenovirus, Oncolytic virus, Akseli Hemminki

TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, today announces that it has submitted an IND for its Phase I trial of immunotherapeutic TILT-123 in ovarian cancer.

Key Points:

TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, today announces that it has submitted an IND for its Phase I trial of immunotherapeutic TILT-123 in ovarian cancer.
The trial will evaluate the companys adenoviral cancer immunotherapy TILT-123, a double cytokine armed oncolytic adenovirus, in combination with KEYTRUDA (pembrolizumab), MSDs anti-PD-1 therapy, in a dose escalation trial in platinum resistant or refractory ovarian cancer patients.
During the first month of the trial, patients will receive TILT-123 monotherapy, and thereafter TILT-123 in conjunction with pembrolizumab.
TILT Biotherapeutics also announces changes to the board of directors, with Jyrki Liljeroos, formerly a board advisor, appointed as Chairman.

TILT Biotherapeutics, Docrates Cancer Center and Helsinki University Hospital Open Cancer Immunotherapy Clinical Trial

Retrieved on:

Wednesday, May 5, 2021

Patients are being treated at Docrates Cancer Center and Helsinki University Hospital (Helsinki, Finland), leading international treatment facilities specializing in diagnostics, treatment and follow-up of cancers.\nThe \xe2\x80\x98TILT-T115\xe2\x80\x99 clinical trial (1) is a phase 1, open-label, dose-escalation study of the company\xe2\x80\x99s oncolytic adenovirus coding for Tumor Necrosis Factor Alpha (TNF alpha) and Interleukin 2 (IL-2), known as TILT-123.

Key Points:

Patients are being treated at Docrates Cancer Center and Helsinki University Hospital (Helsinki, Finland), leading international treatment facilities specializing in diagnostics, treatment and follow-up of cancers.\nThe \xe2\x80\x98TILT-T115\xe2\x80\x99 clinical trial (1) is a phase 1, open-label, dose-escalation study of the company\xe2\x80\x99s oncolytic adenovirus coding for Tumor Necrosis Factor Alpha (TNF alpha) and Interleukin 2 (IL-2), known as TILT-123.
A total of approximately 20 patients will receive TILT-123 as a monotherapy over a three-month period.
It has funding from Lifeline Ventures, angel investors, Business Finland, and the European Innovation Council (EIC).\nDocrates Cancer Center is a private, Finnish-owned, international hospital in Helsinki specializing in individual and comprehensive cancer care.
Docrates provides services for cancer patients throughout the treatment chain from diagnosis to treatments and follow-up.

TILT Biotherapeutics and MSD to Collaborate on Clinical Trial of Adenoviral Cancer Immunotherapeutic TILT-123 in Combination with KEYTRUDA® (pembrolizumab) for Ovarian Cancer

Retrieved on:

Wednesday, April 14, 2021

Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Clinical medicine, Medicine, Cancer treatments, Adenoviridae, Experimental cancer treatments, Virotherapy, Biotechnology, Oncolytic adenovirus, Orphan drugs, Oncolytic virus, Pembrolizumab, Cytokine

During the first month of the trial, patients will receive TILT-123 monotherapy, and thereafter consecutive treatments of TILT-123 in conjunction with pembrolizumab.

Key Points:

During the first month of the trial, patients will receive TILT-123 monotherapy, and thereafter consecutive treatments of TILT-123 in conjunction with pembrolizumab.
The heart of our approach revolves around the use of oncolytic adenoviruses armed with cytokines to boost the patient\xe2\x80\x99s immune response towards the tumor, enabling it to find and destroy cancer cells.
TILT\xe2\x80\x99s lead asset, TILT-123, is a 5/3 chimeric serotype adenovirus armed with two human cytokines; TNF alpha and IL-2.
It has funding from Lifeline Ventures, angel investors, Business Finland, and the European Innovation Council (EIC).

Transgene Presents Initial Phase I Data of TG6002, Highlighting the Potential of the Intravenous Administration of Its Oncolytic Viruses

Retrieved on:

Friday, April 9, 2021

To-date, the only oncolytic virus that has received regulatory approval is only approved for intra-tumoral administration, restricting its use to superficial lesions.

Key Points:

To-date, the only oncolytic virus that has received regulatory approval is only approved for intra-tumoral administration, restricting its use to superficial lesions.
The findings that will be presented at AACR demonstrate the relevance of intravenous administration of Transgenes next generation oncolytic viruses including TG6002.
Based on the safety profile of TG6002, several dose levels have been added to the initial Phase I clinical protocol.
With its proprietary platform Invir.IO, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses.

FDA Authorizes Phase 1 Trial of ImmunityBio’s Novel COVID-19 Vaccine Candidate hAd5; Dual Construct is Designed to Drive Both T Cell and Antibody Immunity

Retrieved on:

Thursday, October 15, 2020

The company anticipates launching a Phase I trial at Irvine, Calif. based Hoag Hospital this month with adult subjects up to age 55.

Key Points:

The company anticipates launching a Phase I trial at Irvine, Calif. based Hoag Hospital this month with adult subjects up to age 55.
The hAd5-COVID-19 vaccine candidate is a novel, engineered, second-generation human adenovirus serotype 5 vaccine.
Furthermore, studies have shown that patients with SARS-CoV infection have long-term T cell memory to the N protein.
ImmunityBios hAd5 second generation adenovirus platform has four deletions which overcome pre-existing adenoviral immunity allowing for multiple administrations.

Aprea Therapeutics Launches Disease Awareness Website for Healthcare Professionals, p53reactivation.com

Retrieved on:

Wednesday, October 14, 2020

Branches of biology, Tumor suppressor genes, Proteins, Cell biology, Apoptosis, Programmed cell death, P53, Cancer, Tumor suppressor, Oncolytic adenovirus

BOSTON, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc.(Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactivate mutant tumor suppressor protein, p53, today announced the launch of p53reactivation.com .

Key Points:

BOSTON, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc.(Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactivate mutant tumor suppressor protein, p53, today announced the launch of p53reactivation.com .
The new website contributes to Apreas disease awareness initiative to educate healthcare professionals on the importance of p53 mutations in cancer and reactivation of mutant p53 as a potential therapeutic option for the treatment of cancer.
Mutations in p53 are present in approximately half of all cancers and are often associated with poor treatment outcomes and resistance to traditional anti-cancer therapies, said Eyal Attar, M.D., Senior Vice President and Chief Medical Officer of Aprea Therapeutics.
Knowledge of the poor prognoses that accompany p53 mutations, the availability of diagnostic tests for their identification, and awareness of mutant p53 reactivation as a potential targeted therapeutic option, may collectively advance detection and treatment for cancer patients with this important and significant unmet medical need.

TILT Biotherapeutics Announces Two Patients Pass Primary Safety Endpoint in European Cancer Immunotherapy Trial

Retrieved on:

Monday, September 28, 2020

Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Biotechnology, Experimental cancer treatments, Virotherapy, Clinical medicine, Medical specialties, Medicine, Adenoviridae, Oncolytic adenovirus, Oncolytic virus, Tumor necrosis factor, Cytokine, Transgene SA

TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, announces it has dosed two patients in a phase 1 clinical trial of its dual cytokine armed oncolytic adenovirus, TILT-123, in Denmarks Herlev hospital in Copenhagen.

Key Points:

TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, announces it has dosed two patients in a phase 1 clinical trial of its dual cytokine armed oncolytic adenovirus, TILT-123, in Denmarks Herlev hospital in Copenhagen.
Of the two patients dosed, both have now passed the trials 36-day primary safety endpoint having received three administrations of TILT-123 at the lowest dose.
TILT-123s clinical trial (1) is a phase 1, open-label, dose-escalation study of the companys oncolytic adenovirus coding for Tumor Necrosis Factor Alpha (TNF alpha) and Interleukin 2.
This should act as a springboard to more European trials, and our first US trials, in other solid tumors.